EXHIBIT 10.25
AMENDMENT No. 12
to
THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT
Dated 08 January 2004
Between
LONZA BIOLOGICS PLC
and
TRUBION PHARMACEUTICALS, INC.
CONFIDENTIAL TREATMENT
THIS AMENDMENT No. 12 ("Twelfth Amendment") is made the 31st day of March 2006
BETWEEN
LONZA BIOLOGICS PLC of 000 Xxxx Xxxx, Xxxxxx, Xxxxxxxxx XX0 0XX, Xxxxxxx
(hereinafter referred to as "LB"), and
TRUBION PHARMACEUTICALS, INC, of 0000 0xx Xxxxxx, Xxxxx 0000, Xxxxxxx, XX 00000,
XXX (herein after referred to as the "Customer")
WHEREAS
A. LB and the Customer entered into a development and manufacturing services
agreement ("the Agreement") dated 08 January 2004, pursuant to which LB agreed
to provide Services to the Customer, and,
B. The Customer now wishes LB to perform additional services under the
Agreement, and,
C. LB is willing to perform such additional services on the terms set out in the
Agreement, and,
D. The parties wish to amend the Agreement in accordance with Clause 13.5
thereto.
NOW THEREFORE IT IS HEREBY AGREED as follows:
1. SCHEDULE 1 OF THE AGREEMENT SHALL BE AMENDED TO INCLUDE THE FOLLOWING:
(a) ***
Inserted into Agreement by Amendment 11.
(b) ***
CONFIDENTIAL TREATMENT
METHOD
TEST NO. CRITERION (LB SOP NUMBER) SPECIFICATION
-------- --------- --------------- -------------
Characteristics
*** *** *** ***
*** *** *** ***
*** *** *** ***
*** *** *** ***
*** *** *** ***
***
*** *** *** ***
***
*** *** *** ***
*** *** ***
***
*** *** ***
***
*** *** *** ***
***
*** *** *** ***
*** *** *** ***
*** *** *** ***
*** *** ***
*** *** ***
*** *** *** ***
*** *** *** ***
***
*** *** *** ***
*** *** *** ***
***
*** *** *** ***
***
*** *** *** ***
*** *** *** ***
*** *** *** ***
Storage and shipping information
Final Formulation Buffer: *** (Pharmaceutical Grade)
Bottling of Bulk Product:
Primary containers: ***
Denominations:
CONFIDENTIAL TREATMENT
-2-
***
Any remaining Product will be filled into ***. If this is not filled
with a tolerance of ***, this will be labelled as a Customer Sample
and will not be released for clinical use.
For the calculation of the total fill volume it is assumed that 1g of
liquid ~ 1ml.
Product Storage Conditions: *** degrees C
Shipment Temperature: *** degrees C
Customer samples (removed during the middle of dispensing):
To be agreed by LB and Customer.
Shipment Temperature: ***
2. SCHEDULE 2 OF THE AGREEMENT SHALL BE AMENDED TO ADD STAGES 36 AND 37 TO
READ AS FOLLOWS:
36 "STAGE 36 - ***
36.1 OBJECTIVE
***
36.2 ACTIVITIES
***
36.3 TIMESCALE
This Stage may commence when the cell bank *** is available for
use, the Process development activities are complete and cGMP
documents are approved.
This Stage shall be complete upon disposition of Product by LB's
Quality department. It is estimated that Product will be
delivered *** from commencement of this Stage. ***. It is
estimated that this shipment could occur *** from commencement of
this Stage.
37 STAGE 37 - ***
37.1 OBJECTIVE
***
CONFIDENTIAL TREATMENT
-3-
37.2 ACTIVITIES
***
37.3 TIMESCALE
This Stage may commence when the cell bank *** is available for
use, the Process development activities are complete and cGMP
documents are approved.
This Stage shall be complete upon disposition of Product by LB's
Quality department. It is estimated that Product will be
delivered *** from commencement of this Stage ***. It is
estimated that this shipment could occur *** from commencement of
this Stage.
CONFIDENTIAL TREATMENT
-4-
SCHEDULE 3 TO THE AGREEMENT SHALL BE AMENDED TO INCLUDE PROVISION FOR PAYMENT
FOR THE ABOVE MENTIONED ADDITIONAL SERVICES, AS SET OUT BELOW HERETO. INVOICES
FOR THESE ADDITIONAL SERVICES SHALL BE ISSUED, AND CUSTOMER PAYMENTS SHALL BE
MADE, IN ***:
"1. PRICE
***
2. PAYMENT
FOR STAGE 36
*** upon removal of an ampoule out of freeze.
*** upon completion of Stage 36.
***
FOR STAGE 37
*** upon removal of an ampoule out of freeze.
*** upon completion of Stage 37.
*** will be invoiced separately
CONFIDENTIAL TREATMENT
-5-
LONZA
SAVE AS HEREIN PROVIDED ALL OTHER TERMS AND CONDITIONS OF THE AGREEMENT SHALL
REMAIN IN FULL FORCE AND EFFECT.
AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.
Signed for and on behalf of
LONZA BIOLOGICS PLC /s/ Xxx Xxxxxx
----------------------------------------
VP Global Biologics Quality
TITLE
Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC /s/ Xxxxxxx X. Xxxxxx
----------------------------------------
Senior VP, Research & Development
TITLE
CONFIDENTIAL TREATMENT
